

# Oncology Clinical Pathways

## Mesothelioma

---

October 2024 – V3.2024



Choose **VA**



**SHOULDER to SHOULDER**  
Every Step of the Way

**VA**



U.S. Department  
of Veterans Affairs

# Table of Contents

- [Presumptive Conditions](#).....3
- [Pleural Epithelioid](#).....4
- [Sarcomatoid or Biphasic](#).....5
- [Molecular Testing Table](#).....6




# Mesothelioma – Presumptive Conditions

VA automatically presumes that certain disabilities were caused by military service. This is because of the unique circumstances of a specific Veteran's military service. If a presumed condition is diagnosed in a Veteran within a certain group, they can be awarded disability compensation.

Mesothelioma is not currently listed as a presumptive condition.

For more information, please visit [U.S. Department of Veterans Affairs - Presumptive Disability Benefits \(va.gov\)](https://www.va.gov/opa/whatsnew/presumptive-disability-benefits)

# Mesothelioma – Pleural Epithelioid



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email [CancerClinicalTrialsNavigation@va.gov](mailto:CancerClinicalTrialsNavigation@va.gov).

**\* Pleural Epithelioid** comprehensive genomic profiling (CGP) and PD-L1 expression is not routinely recommended in mesothelioma


**<sup>a</sup> Refer to Genetics for Counseling** germline BAP1 alterations have been described in patients with mesothelioma; referral to genetics is recommended

**<sup>c</sup> Candidate for Bevacizumab** if ECOG PS 0-2; not amenable to curative surgery; due to anti-VEGF effects patients with the following should not receive bevacizumab: non-healing wound/fracture, major surgery in prior 4 weeks, bleeding disorder or coagulopathy, recent history of GI perforation, unstable cardiac condition [uncontrolled HTN, arterial thromboembolism, symptomatic CHF (NYHA II-IV), recent MI or CVA, uncontrolled angina or arrhythmia], use of antiplatelet therapy (aspirin ≥325 mg/day, dipyridol, ticlopidine, dipyridamole), anti-vitamin K drugs at curative dose, LMWH at curative dose, use of NSAIDS

**<sup>d</sup> Pleurectomy** patient a candidate if N0 disease, low burden pleural disease, limited chest wall involvement

**<sup>e</sup> Progression** if patient is symptomatic, consider referral to Radiation Oncology for palliative therapy

# Mesothelioma – Sarcomatoid or Biphasic



Clinical trial(s) always considered on pathway. For assistance finding a clinical trial, email [CancerClinicalTrialsNavigation@va.gov](mailto:CancerClinicalTrialsNavigation@va.gov).

<sup>a</sup> **Sarcomatoid or Biphasic** comprehensive genomic profiling (CGP) and PD-L1 expression is not routinely recommended in mesothelioma  
<sup>b</sup> **Refer to Genetics for Counseling** germline BAP1 alterations have been described in patients with mesothelioma; referral to genetics is recommended  
<sup>c</sup> **Ipilimumab** dosing of 1mg/kg every 6 weeks  
<sup>d</sup> **Progression** if patient is symptomatic, consider referral to Radiation Oncology for palliative therapy

# Mesothelioma – Molecular Testing Table

Eligibility	Test Category	Test Type	Recommended Vendors	NPOP Coverage	Specimen Type
Mesothelioma	No molecular testing is currently required for standard prognostication and therapy.				